Sensei Biotherapeutics (SNSE)

• Market cap: $39.8M
• 1 day: 3.31%
• 5 days: -3.01%
• 1 month: -5.79%
• 3 months: 231.16%
• 6 months: 252.63%
• Year to date: 227.05%
• 1 year: 243.04%
• 5 years: -89.5%
• 10 years: -91.65%
• Sector: Healthcare
• Industry: Biotechnology

About: Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).

Employees: 15